On the Rox | Rebooting JACC: The New Rules of Science

Behind the Science: ECG Prediction of Stroke | JACC

HFpEF Without Obesity: What Coronary Microcirculation Tells Us | JACC Baran

What Autopsy Reveals About MINOCA and Sudden Cardiac Death | JACC Baran

Can Sacubitril/Valsartan Prevent Anthracycline Cardiotoxicity? | JACC CardioOncology Journal Club

How to Recognize Kounis Syndrome After Hymenoptera Stings and Streptokinase | JACC: Asia Pulse

Beyond the BMI: The Hidden Heart Risk | JACC: Asia Pulse

Celebrating Two Years: Dr. Harlan Krumholz Reflecting on His Time as JACC Editor-in-Chief | JACC

Behind The Science: Radiomic Profiling of Epicardial Fat for Heart Failure Prediction | JACC

Remnant Cholesterol: Small Name, Big ASCVD Risk | JACC Baran

ACC Peer Review Certificate Program Essentials

Program Signaling in CV Fellowship Recruitment | JACC

Behind the Science: Using Coronary Calcium to Improve Lipoprotein(a) Risk Prediction | JACC

Post-AF Ablation Anticoagulation: How Long Is Long Enough? | JACC Baran

Behind the Science: Excess Cardiovascular Mortality Among Black Americans | JACC

2025 Impact Factor | JACC: Asia

PREVUE-VALVE | JACC

Seven Year Outcomes of Evolut Low Risk | JACC

Ultra-Low-Dose CAC in the Photon-Counting Era | JACC Baran

ACC's Fuster Prevention Forum 2026

The Rise of PROs: What Traditional Risk Scores May Be Missing | JACC Baran

ACC WIC 2026 Spring Book Club

After PCI, What Matters Most? Heart Failure, Bleeding, or Recurrent MI? | JACC Baran

The Power of ACC Membership

Side Branch Treatment for Bifurcation Revascularization: KISS Trial | JACC: CV Interventions

DCB vs DES in Noncomplex Coronary Bifurcation Lesions: REC CAGEFREE I | JACC: CV Interventions

HFpEF and HFmrEF: Can KCCQ-12 Replace KCCQ-23? | JACC Baran

Expert Perspectives on the 2026 Acute PE Guideline | JACC Journal Club

Should Interventionalists Get an MBA? Wayne Batchelor, MD, MHS, MBA Responds |JACC:CV Interventions

Should Interventionalists Get an MBA? Kirk Garratt, MD, MSc Responds | JACC: CV Interventions

Should Interventionalists Get an MBA? J. Dawn Abbott, MD Responds | JACC: CV Interventions

Should Interventionalists Get an MBA? Deepak Bhatt, MD, MPH, MBA Responds | JACC: CV Interventions

On the Rox | Get to Know Your Leaders

Can AI Predict AF Recurrence After Cardioversion? | JACC Baran

Behind the Science: NPR-1 Agonist for Resistant Hypertension | JACC

Beyond Clinical Excellence: Leadership Insights from ACC President Christopher Kramer | JACC

Global Hypertension 2000 to 2020 | JACC

Mitral Stenosis: Beyond Rheumatic Disease | JACC Baran

ACC.26 Meeting in Review

AF Ablation and the Brain: Does It Improve Blood Flow and Cognition? | JACC Baran

Founding the Japanese Onco-Cardiology Society: Lessons for Young Cardiologists | JACC: Asia Pulse

Risk of CVD in Cancer Survivors After Systemic Treatment | JACC: CardioOncology Journal Club

Updating Training for Tomorrow’s Electrophysiologists | HRS | JACC

Acute PE in Practice: An APAC View on the New AHA/ACC Guideline | JACC Baran

TREAT-PVC | HRS | JACC: Clinical EP

Insights from the CLEAR-VT Registry | HRS | JACC: Clinical EP

Marfan Syndrome: Timing Surgery Through Genetics | JACC Baran

Behind the Science: AI in Cardiovascular Clinical Trials | JACC

Insights From ORBITA-CTO | JACC Journal Club

Unraveling HCM Heterogeneity Using Circulating microRNAs | JACC Baran

Cardiogenic Shock From ICI Myocarditis With Predominant RV Failure | ACC.26 | JACC: CardioOncology

The Future of Cardio-Oncology: Progress and Priorities | ACC.26 | JACC: CardioOncology

Risk Scores for Transcatheter Tricuspid Interventions | JACC: CV Interventions

Frequency and Outcomes of Acute Hemodynamic Instability Following TTVR | JACC: CV Interventions

Cardiovascular Adverse Events Associated with Bispecific TCE Therapy | JACC: CardioOncology

Why Lowering LDL Below 55 Matters for ASCVD Patients | Asia Pulse

Rethinking Long-Term Beta‑Blocker Use After MI | Asia Pulse

Clopidogrel vs Aspirin—10-Year Real-World Results | Asia Pulse

Chagas Cardiomyopathy — Epidemiology Through Modern Clinical Trials | JACC Baran

Behind The Science: Social Risk and Mortality in Veterans With Cardiovascular Disease | JACC